<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086536</url>
  </required_header>
  <id_info>
    <org_study_id>2021-P2-224-01</org_study_id>
    <nct_id>NCT05086536</nct_id>
  </id_info>
  <brief_title>Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis</brief_title>
  <official_title>Re-compensation and Its Clinical Characteristics in Treatment-naïve HBV Decompensated Cirrhosis on Antiviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Baotou Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled&#xD;
      at the first episode of decompensation (ascites or variceal hemorrhage). Patients were&#xD;
      followed up every 6 months until death /liver transplantation or for 5 years. Clinical data&#xD;
      from medical records about past history, first decompensated events, second /further&#xD;
      decompensated events, HCC, and death/ liver transplantation were retrospectively collected.&#xD;
      In this retrospective study, the incidence of re-compensation and its clinical&#xD;
      characteristics were mainly explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled&#xD;
      at the first episode of decompensation (ascites or variceal hemorrhage). Patients were&#xD;
      followed up every 6 months until death /liver transplantation or for 5 years. WBC, RBC, HGB,&#xD;
      PLT, CRP, PT, PTA, INR, ALT, AST, TB, DB, ALB, GLO, ALP, GGT, CHE, BUN, Cr, Na, GLU, CHOL,&#xD;
      TG, HDL-C, LDL-C, AFP, HBsAg, HBV-DNA, LSM, BUS, MRI/CT and gastroscope from medical records&#xD;
      about past history, first decompensated events, second /further decompensated events, HCC,&#xD;
      and death/ liver transplantation were retrospectively collected. This retrospective study&#xD;
      aimed to explore the incidence of re-compensation and its clinical characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of re-compensation</measure>
    <time_frame>Year 5</time_frame>
    <description>Patients who did not occur further decompensation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of re-compensation</measure>
    <time_frame>Year 1, 2, 3, and 4</time_frame>
    <description>Patients who did not occur further decompensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual incidence of second decompensation</measure>
    <time_frame>Year 1, 2, 3, 4, and 5</time_frame>
    <description>Patients who occurred second decompensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of liver-related death / liver transplantation</measure>
    <time_frame>Year 1, 2, 3, 4, and 5</time_frame>
    <description>Patients who died of decompensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of HCC</measure>
    <time_frame>Year 1, 2, 3, 4, and 5</time_frame>
    <description>Patients who occurred HCC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of Child-Pugh score in re-compensated and not re-compensated group</measure>
    <time_frame>Year 1, 2, 3, 4, and 5</time_frame>
    <description>Child-Pugh</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of MELD score in re-compensated and not re-compensated group</measure>
    <time_frame>Year 1, 2, 3, 4, and 5</time_frame>
    <description>MELD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of APRI score in re-compensated and not re-compensated group</measure>
    <time_frame>Year 1, 2, 3, 4, and 5</time_frame>
    <description>APRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of FIB-4 score in re-compensated and not re-compensated group</measure>
    <time_frame>Year 1, 2, 3, 4, and 5</time_frame>
    <description>FIB-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of liver stiffness values measured by Transient Elastography in re-compensated and not re-compensated group</measure>
    <time_frame>Year 1, 2, 3, 4, and 5</time_frame>
    <description>Liver stiffness</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Decompensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>early stage decompensation cohort</arm_group_label>
    <description>Patients occurred first decompensated events and initiating nucleoside analogs (NUCs) based treatment within 3 months were retrospectively included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>This is a retrospective and observational study.</description>
    <arm_group_label>early stage decompensation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HBV-decompensated cirrhosis patients who occurred first decompensated events and initiated&#xD;
        antiviral therapy within 3 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ascites and/or variceal hemorrhage (VH) as the first decompensated events;&#xD;
&#xD;
          2. Initiating antiviral therapy within 3 months of the first decompensated events;&#xD;
&#xD;
          3. Clinical parameters were available at the first decompensated events, including PLT,&#xD;
             ALT, ALB, TB, PT/INR, Cr, HBV DNA, BUS,&#xD;
&#xD;
          4. Clinical outcomes were classified:&#xD;
&#xD;
               1. Without further decompensation: medical records at year-1, year 2 to 4, and&#xD;
                  year-5 were available.&#xD;
&#xD;
               2. With ≥ 2 episodes of decompensation: medical records for decompensation were&#xD;
                  available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hepatocellular carcinoma prior to /within 6 months of first decompensated events;&#xD;
&#xD;
          2. Liver transplantation /death within 6 months of first decompensated events;&#xD;
&#xD;
          3. complicated with other chronic liver diseases, including HCV, DILI, AIH, NAFLD, ALD.&#xD;
&#xD;
          4. Any complication of severe heart, lung, kidney, brain, blood diseases or other severe&#xD;
             systematic diseases;&#xD;
&#xD;
          5. Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong You, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong You, Doctor</last_name>
    <phone>861063139019</phone>
    <email>youhong30@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jialing Zhou, Master</last_name>
    <phone>010-63138665</phone>
    <email>zhoujialing11@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoning Wu, Doctor</last_name>
      <phone>8610-63138665</phone>
      <email>wuxiaoningbs@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhiying He</last_name>
      <phone>13311314386</phone>
      <email>zhiyinghe2012@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hong You, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10069</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Chen, Doctor</last_name>
      <phone>13810594713</phone>
      <email>jiechenokcat0215@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhongjie Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XiangYa Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yixiang Zheng, Doctor</last_name>
      <phone>15111002627</phone>
      <email>418414718@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yan Huang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Baotou Medical Coll</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lianhui Zhao, Doctor</last_name>
      <phone>18810825004</phone>
      <email>18253163004@163.com</email>
    </contact>
    <investigator>
      <last_name>Chunqing Zhang, Docote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qiuju Tian, Doctor</last_name>
      <phone>18610827822</phone>
      <email>tianqiuju_1017@163.com</email>
    </contact>
    <investigator>
      <last_name>Wei Rao, Docotr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanqin Hao, Doctor</last_name>
      <phone>13994262902</phone>
      <email>13994262902@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanqin Hao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liaoyun Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, Kim TY, Sohn JH, Tak WY, Han KH. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015 Jun;61(6):1809-20. doi: 10.1002/hep.27723. Epub 2015 Mar 18.</citation>
    <PMID>25627342</PMID>
  </reference>
  <reference>
    <citation>Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016 Sep;65(3):524-31. doi: 10.1016/j.jhep.2016.05.010. Epub 2016 May 17.</citation>
    <PMID>27212241</PMID>
  </reference>
  <reference>
    <citation>Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, Manzano ML, Lorente S, Testillano M, Xiol X, Molina E, González-Diéguez L, Otón E, Pascual S, Santos B, Herrero JI, Salcedo M, Montero JL, Sánchez-Antolín G, Narváez I, Nogueras F, Giráldez Á, Prieto M, Forns X, Londoño MC. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol. 2017 Dec;67(6):1168-1176. doi: 10.1016/j.jhep.2017.08.008. Epub 2017 Aug 24.</citation>
    <PMID>28842296</PMID>
  </reference>
  <reference>
    <citation>Perricone G, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagiuoli S, Belli LS; European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. Liver Int. 2018 Dec;38(12):2170-2177. doi: 10.1111/liv.13878. Epub 2018 May 25.</citation>
    <PMID>29750389</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Hong You</investigator_full_name>
    <investigator_title>Vice director</investigator_title>
  </responsible_party>
  <keyword>re-compensation</keyword>
  <keyword>treatment-naive</keyword>
  <keyword>HBV</keyword>
  <keyword>decompensation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

